46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
Showing 1 to 10 of 3,932 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05274243 (ClinicalTrials.gov) | September 2022 | 1/3/2022 | 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis | 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: 2-HOBA;Other: Placebo | Vanderbilt University Medical Center | NULL | Not yet recruiting | 18 Years | N/A | All | 32 | Phase 2 | United States |
| 2 | NCT05267431 (ClinicalTrials.gov) | June 2022 | 14/2/2022 | Outcomes of Biological Therapy on Rheumatoid Arthritis | Outcomes of Different Biological Therapy on Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Biological Drug | Sohag University | NULL | Not yet recruiting | 18 Years | N/A | All | 200 | Egypt | |
| 3 | NCT04269993 (ClinicalTrials.gov) | April 1, 2022 | 12/2/2020 | Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis | Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients With Rheumatoid or Psoriatic Arthritis Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients ... | Rheumatoid Arthritis;Psoriatic Arthritis | Drug: Cannabis: placebo and medium THC/medium CBD | Brown University | NULL | Not yet recruiting | 18 Years | 65 Years | All | 76 | Phase 2 | NULL |
| 4 | NCT05264025 (ClinicalTrials.gov) | April 2022 | 10/1/2022 | Fexofenadine in Patients With Active Rheumatoid Arthritis | Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid | Rheumatoid Arthritis | Drug: Fexofenadine;Drug: Placebo | October 6 University | NULL | Not yet recruiting | 18 Years | 60 Years | All | 80 | Phase 1/Phase 2 | NULL |
| 5 | NCT05166304 (ClinicalTrials.gov) | April 2022 | 8/12/2021 | Rebamipide in Patients With Active Rheumatoid Arthritis | Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Rebamipide;Drug: Placebo | October 6 University | NULL | Not yet recruiting | 18 Years | 60 Years | All | 100 | Phase 1/Phase 2 | NULL |
| 6 | NCT05246280 (ClinicalTrials.gov) | March 2, 2022 | 16/12/2021 | Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFa Therapy Response in Moderate to Severe Active RA Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFa Therapy Response in Moderate to Severe ... | Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFa Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFa Therapy Response in P ... | Rheumatoid Arthritis | Drug: TC99m-tilmanocept | Navidea Biopharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 523 | Phase 3 | United States |
| 7 | NCT05246293 (ClinicalTrials.gov) | March 2, 2022 | 17/1/2022 | Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease. | Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease (RAILDTo Trial). Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial ... | Rheumatoid Arthritis;Interstitial Lung Disease | Drug: Tofacitinib | National Institute of Respiratory Diseases, Mexico | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | Mexico |
| 8 | NCT05238896 (ClinicalTrials.gov) | March 1, 2022 | 4/1/2022 | BARIcitinib Cognitive Emotional and Neural signaTuRE | BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE) | Rheumatoid Arthritis | Drug: Baricitinib Oral Tablet [Olumiant];Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | 75 Years | All | 80 | Phase 4 | France |
| 9 | NCT05257174 (ClinicalTrials.gov) | March 2022 | 28/1/2022 | The Effects of Jing Si Herbal Tea Liquid Packets on Fatigue in Patients With Inflammatory Arthritis | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Jing Si Herbal Tea Liquid Packets on Fatigue in Patients With Inflammatory Arthritis A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Jing Si Herbal Tea L ... | Arthritis;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Fatigue | Dietary Supplement: Jing Si Herbal Tea LIQUID PACKETS;Dietary Supplement: Placebo | Buddhist Tzu Chi General Hospital | NULL | Not yet recruiting | 20 Years | 99 Years | All | 150 | N/A | Taiwan |
| 10 | NCT05236491 (ClinicalTrials.gov) | March 2022 | 10/2/2022 | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases | Rheumatoid Arthritis;Autoimmune Rheumatologic Disease;Systemic Lupus Erythematosus;Systemic Vasculitis;Systemic Sclerosis;Scleroderma;Undifferentiated Connective Tissue Diseases;Overlap Connective Tissue Disease;Immunosuppression Rheumatoid Arthritis;Autoimmune Rheumatologic Disease;Systemic Lupus Erythematosus;Systemic Vasculit ... | Biological: COVID-19 vaccine | Paul R Fortin | Canadian Institutes of Health Research (CIHR) | Not yet recruiting | 18 Years | N/A | All | 287 | Phase 2/Phase 3 | NULL |